Advisor Group’s Heron Therapeutics HRTX Stock Holding History

Advisor Group’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$21K	Sell	878 -199	-18%	-$4.4K	﹤0.01%	3924
2019 Q3	$20K	Buy	1,077 +568	+112%	+$10.5K	﹤0.01%	3959
2019 Q2	$10K	Sell	509 -907	-64%	-$18.1K	﹤0.01%	4369
2019 Q1	$35K	Buy	1,416 +695	+96%	+$18.2K	﹤0.01%	3628
2018 Q4	$19K	Buy	721 +468	+185%	+$12.9K	﹤0.01%	3834
2018 Q3	$8K	Buy	253 +7	+3%	+$261	﹤0.01%	4381
2018 Q2	$10K	Sell	246 -5	-2%	-$159	﹤0.01%	4075
2018 Q1	$7K	Buy	251 +204	+434%	+$4.63K	﹤0.01%	4267
2017 Q4	$1K	Buy	47 +8	+21%	+$130	﹤0.01%	4822
2017 Q3	$1K	Hold	39	–	–	﹤0.01%	4677
2017 Q2	$1K	Hold	39	–	–	﹤0.01%	4628
2017 Q1	$1K	Hold	39	–	–	﹤0.01%	4530
2016 Q4	$1K	Sell	39 -19	-33%	-$298	﹤0.01%	4356
2016 Q3	$1K	Buy	58 +39	+205%	+$724	﹤0.01%	4301
2016 Q2	$0	Buy	+19	New	+$371	﹤0.01%	4434

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Advisor Group's HRTX Position: Q4 2019 in Review

Advisor Group reduced its Heron Therapeutics (HRTX) stake by 18% in Q4 2019, selling an estimated $4.4K and leaving 878 shares worth $21K. The position accounts for ﹤0.01% of the portfolio, ranked #3924.

Advisor Group first reported a position in HRTX in Q2 2016 and has held it in 15 quarters since. The position peaked at $35K in Q1 2019. 199 funds tracked by Wall St. Rank hold HRTX as of Q4 2019.

Advisor Group held 878 shares of Heron Therapeutics worth $21K as of Q4 2019.
Advisor Group sold 199 Heron Therapeutics shares in Q4 2019, an estimated $4.4K.
Heron Therapeutics made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #3924 holding.
Advisor Group first reported a position in Heron Therapeutics in Q2 2016 and has held it in 15 quarters since.
Advisor Group's Heron Therapeutics position peaked at $35K in Q1 2019.
199 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.